Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 284

    1.

    Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.

    Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U.

    Arthritis Res. 2001;3(4):247-52. Epub 2001 Apr 10.

    PMID:
    11438043
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.

    Arthritis Rheum. 2002 Mar;46(3):614-24.

    PMID:
    11920396
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P.

    Arthritis Rheum. 1998 Dec;41(12):2196-204.

    PMID:
    9870876
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.

    Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M.

    Arthritis Rheum. 1996 Jul;39(7):1092-101.

    PMID:
    8670316
    [PubMed - indexed for MEDLINE]
    5.

    Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.

    Arthritis Rheum. 2002 Dec;46(12):3143-50.

    PMID:
    12483717
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

    Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group.

    Aliment Pharmacol Ther. 2002 Mar;16(3):399-406.

    PMID:
    11876692
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.

    Arthritis Rheum. 2004 Feb;50(2):353-63.

    PMID:
    14872476
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.

    Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US.

    Gastroenterology. 1999 Jul;117(1):58-64.

    PMID:
    10381910
    [PubMed - indexed for MEDLINE]
    10.

    Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.

    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.

    Arthritis Rheum. 2004 Feb;50(2):364-71.

    PMID:
    14872477
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

    Clin Ther. 2003 Jun;25(6):1700-21.

    PMID:
    12860493
    [PubMed - indexed for MEDLINE]
    12.

    Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.

    J Rheumatol. 2003 Dec;30(12):2563-71.

    PMID:
    14719195
    [PubMed - indexed for MEDLINE]
    13.

    Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME.

    Ann Intern Med. 1999 Mar 16;130(6):478-86.

    PMID:
    10075615
    [PubMed - indexed for MEDLINE]
    14.

    Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.

    Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF.

    Am J Gastroenterol. 2006 Apr;101(4):793-7.

    PMID:
    16635225
    [PubMed - indexed for MEDLINE]
    15.

    The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.

    Bresnihan B.

    Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):17-20.

    PMID:
    11357167
    [PubMed - indexed for MEDLINE]
    16.

    Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

    Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

    PMID:
    19560810
    [PubMed - indexed for MEDLINE]
    17.

    A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.

    Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M Jr.

    J Formos Med Assoc. 2004 Aug;103(8):618-23.

    PMID:
    15340661
    [PubMed - indexed for MEDLINE]
    18.

    A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.

    Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C 3rd, Solinger A, Macri M; 990136 Study Group.

    J Rheumatol. 2005 Dec;32(12):2303-10.

    PMID:
    16331754
    [PubMed - indexed for MEDLINE]
    20.

    Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.

    Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX.

    Chin Med J (Engl). 2008 Apr 5;121(7):615-9.

    PMID:
    18466681
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk